Accelr8 Announces Results for Rapid Diagnostics with ICU Specimens
Accelr8 Technology Corporation announced results presented at the 51st ICAAC held in Chicago on September 17.
As previously announced in July, the presenters received an award for an 'outstanding presentation of an abstract accepted by ICAAC.' The presentation title is 'Same-Shift ID Directly from Respiratory Specimens by Automated Microscopy.' Accelr8 collaborated with investigators at the Barnes-Jewish Hospital in St. Louis for the study, using Accelr8´s BACcel™ rapid diagnostic system.
The study reported results with 53 bacteria-positive lung specimens from ICU patients. Of these, 16 were positive for the two most common ICU pathogens that can express multi-drug resistance (MDR)Staphylococcus aureus and Pseudomonas aeruginosa. The latter Gram-negative organism is one of the most complex and difficult to treat MDR threats found in hospital-acquired infections.
Accelr8´s BACcel™ rapid diagnostic system correctly identified 9/9 S. aureus and 7/7 P.aeruginosa directly from specimen samples. It also correctly identified the lack of these target organisms in the remaining 37 specimens, yielding detection sensitivity and specificity of 100% and 100%, respectively.
The Accelr8 Web site has a downloadable copy of the presentation at
ICAAC (www.icaac.org) is the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Organized by the American Society for Microbiology (www.asm.org), ICAAC is a major global congress for Clinical Microbiology and Infectious Diseases Medicine.
According to David Howson, Accelr8´s president, 'we are honored by the recognition from ICAAC´s review committee. Results in our outside studies continue to strongly support the system´s accuracy and speed. The BACcel™ system continues as the only new technology to demonstrate multiple organism quantitative identification with multiple antibiotic resistance detection. The BACcel system stands alone in directly confronting the relentlessly advancing global pandemic of multiple antibiotic resistance.'
Source: Accelr8 Technology Corporation View latest company information
Posted: September 20, 2011
[will open your email client]